Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RICE: Concurrent Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer
NCT05621707Phase 2Active, not recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Nov 2022
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanghai Chest Hospital. Primary endpoint: Overall Survival Rate at 2 years. Started Nov 2022; status: active, not recruiting.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05621707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621707.